Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | CASP1 | P29466 | 1/20 | 0.54 |
| ▸ | CASP7 | P55210 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.44 |
| ▸ | CDK2 | P24941 | 2/20 | 0.44 |
| ▸ | ACHE | P22303 | 2/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.42 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16640325 | 0.87 | CCNA2 (0.46) | MAPTTDP1TSHRMAPK1CASP1 | |
| SCHEMBL16640332 | 0.84 | MAPT (0.49) | MAPTTDP1TSHRMAPK1CASP1 | |
| SCHEMBL16640331 | 0.83 | USP2 (0.43) | MAPTTDP1TSHRMAPK1CASP1 | |
| SCHEMBL16640342 | 0.83 | CDK4 (0.41) | MAPTTDP1TSHRMAPK1CASP1 | |
| SCHEMBL12383077 | 0.83 | HDAC3 (0.40) | MAPTTDP1TSHRMAPK1CASP1 | |
| SCHEMBL18237637 | 0.81 | MAPT (0.61) | MAPTTDP1TSHRMAPK1CASP1 | |
| SCHEMBL23795749 | 0.80 | L3MBTL1 (0.37) | MAPTTDP1TSHRMAPK1CASP1 | |
| SCHEMBL13316492 | 0.80 | ATM (0.36) | MAPTTDP1TSHRMAPK1CASP1 | |
| SCHEMBL19132024 | 0.79 | TSHR (0.51) | MAPTTDP1TSHRMAPK1CASP1 | |
| SCHEMBL16640333 | 0.79 | MAPT (0.54) | MAPTTDP1TSHRMAPK1CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024050742-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING KRAS G12D VIA UBIQUITIN PROTEASOME PATHWAY | NIKANG THERAPEUTICS, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240024318-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-11746120-B2 | Stat degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230234953-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20230219945-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| WO-2023116835-A1 | MULTI-PROTEIN DEGRADATION AGENT HAVING IMIDE SKELETON | 苏州开拓药业股份有限公司 | 2023-06-29 | — | — | WO | disclosed |
| US-11679109-B2 | SMARCA degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-20230149549-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-18 | — | — | US | disclosed |
| US-11563187-B2 | Nitrogen-containing compound-containing compound and organic electroluminescence device including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-01-24 | — | — | US | disclosed |
| US-20190148652-A1 | NITROGEN-CONTAINING COMPOUND-CONTAINING COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2019-05-16 | — | — | US | disclosed |
| US-9947881-B2 | Platinum complexes and devices | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2018-04-17 | — | — | US | disclosed |
| US-9931407-B2 | Silicon based drug conjugates and methods of using same | BLINKBIO, INC. (US) | 2018-04-03 | — | — | US | disclosed |
| US-9931407-B2 | Silicon based drug conjugates and methods of using same | BLINKBIO, INC. (US) | 2018-04-03 | — | — | US | disclosed |
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. | 2017-07-20 | — | — | US | disclosed |
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. | 2017-07-20 | — | — | US | disclosed |
| US-20170012224-A1 | PLATINUM COMPLEXES AND DEVICES | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY | 2017-01-12 | — | — | US | disclosed |
| WO-2016183359-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. (US) | 2016-11-17 | — | — | WO | disclosed |
| US-9385329-B2 | Platinum complexes and devices | Arizona Board of Regents on behalf of Arizona State University and Universal Display Corporation (US) | 2016-07-05 | — | — | US | disclosed |
| US-20150105556-A1 | PLATINUM COMPLEXES AND DEVICES | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | MDM2, TP53, MDM4 | MAPT 1460/4885TDP1 409/4885TSHR 3455/4885 |
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | CD44, MSN, AS3MT | MAPT 1162/4885TDP1 2304/4885TSHR 2393/4885 |
| US-20230234953-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | MAPT 2459/4885TDP1 236/4885TSHR 3319/4885 |
| US-20240024318-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCA2, SMARCC2 | MAPT 3823/4885TDP1 151/4885TSHR 4388/4885 |
| US-20230149549-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCB1, SMARCE1 | MAPT 1203/4885TDP1 1914/4885TSHR 4066/4885 |
| US-11746120-B2 | Stat degraders and uses thereof | STAT4, STAT1, STAT3 | MAPT 3167/4885TDP1 779/4885TSHR 1768/4885 |
| US-20230219945-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | MAPT 2459/4885TDP1 236/4885TSHR 3319/4885 |
| US-11679109-B2 | SMARCA degraders and uses thereof | SMARCA1, SMARCA2, SMARCC2 | MAPT 3823/4885TDP1 151/4885TSHR 4388/4885 |
| US-20190148652-A1 | NITROGEN-CONTAINING COMPOUND-CONTAINING COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THE SAME | L1CAM, C1S, CHRM1 | MAPT 3470/4885TDP1 3166/4885TSHR 2642/4885 |
| US-20170012224-A1 | PLATINUM COMPLEXES AND DEVICES | OXA1L, OCIAD1, OCIAD2 | MAPT 1431/4885TDP1 1768/4885TSHR 3038/4885 |
| US-11563187-B2 | Nitrogen-containing compound-containing compound and organic electroluminescence device including the same | L1CAM, C1S, CHRM1 | MAPT 3470/4885TDP1 3166/4885TSHR 2642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.